Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Prices $3.2B in Senior Notes to Finance Life Tech Deal

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today announced that it has priced $3.2 billion worth of senior notes that will help fund a portion of its pending $13.6 billion acquisition of Life Technologies.

The firm has priced four series of notes: $900 million aggregate principal amount of 1.30 percent senior notes due 2017; $900 million aggregate principal amount of 2.40 percent senior notes due 2019; $1 billion aggregate principal amount of 4.15 percent senior notes due 2024; and $400 million aggregate principal amount of 5.30 percent senior notes due 2044. The notes will pay interest on a semi-annual basis.

The firm expects to close the issuance of the notes on Dec. 11.

Yesterday Fitch Ratings downgraded its long-term issuer default rating on Thermo Fisher to 'BBB' from 'BBB+' and assigned a 'BBB' rating to Thermo Fisher's proposed senior notes.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.